RT Journal Article
T1 Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
A1 Meca-Lallana, J. E.
A1 Oreja-Guevara, C.
A1 Munoz, D.
A1 Olascoaga, J.
A1 Pato, A.
A1 Ramio-Torrenta, L.
A1 Meca-Lallana, V.
A1 Hernandez, M. A.
A1 Marzo, M. E.
A1 Alvarez- Cermeno, J. C.
A1 Rodriguez-Antigueedad, A.
A1 Montalban, X.
A1 Fernandez, O.
A1 Spanish Gilenya Registry Investi, 
K1 Real-world evidence
K1 Clinical-practice
K1 Oral fingolimod
K1 Efficacy
K1 Persistence
K1 Experience
K1 Therapy
K1 Trial
K1 Rwe
AB Objective To describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.Methods An observational, retrospective/prospective, multicenter case registry, including all patients with relapsing-remitting MS (RRMS) starting treatment with fingolimod in 43 centers in Spain. Analyses were performed in the overall population and in subgroups according to prior disease-modifying therapy (DMT): glatiramer acetate/interferon beta-1 (BRACE), natalizumab, other treatment, or naive.Results Six hundred and sixty-six evaluable patients were included (91.1% previously treated with at least one DMT). The mean annualized relapse rate (ARR) prior to fingolimod was 1.12, and the mean EDSS at fingolimod initiation was 3.03. Fingolimod reduced the ARR by 71.4%, 75%, 75.5%, and 80.3%, after 1, 2, 3 and 4 years, respectively (p
PB Public library science
SN 1932-6203
YR 2021
FD 2021-10-13
LK https://hdl.handle.net/10668/28225
UL https://hdl.handle.net/10668/28225
LA en
DS RISalud
RD Apr 12, 2025